A Recruiting Challenge for One of the Most Pivotal Clinical Trials of Our Lifetime
With the eyes of the world upon on them, a biotechnology company’s COVID-19 Phase III clinical trial inched closer to its target enrollment of 30,000 participants but was not meeting one milestone: inclusion of participants from communities that have historically been underrepresented in clinical trials and are disproportionately impacted by COVID-19.
During the final stretch of the enrollment period, the sponsor needed to quickly reach unmet diversity and inclusion goals. Fearful that a lack of diversity would slow down its remarkably fast progress to date, the sponsor partnered with Citeline to leverage Citeline Connect in rapidly filling the enrollment gap.
We want to ensure we have data for all the people who could benefit and be protected.
